Christoph Rummelt

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

Nimitha R. Mathew, Francis Baumgartner, Lukas M. Braun et al. · Nature Medicine · 2018 · 283 citations · Full text

Cell Therapy, Flt3-itd-mutant Leukemia Cells, Immunology +7

Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo

Christoph Rummelt, Sivahari Prasad Gorantla, Manja Meggendorfer et al. · Leukemia · 2020 · 45 citations

Flt3 Kinase Inhibitors, Jak-mutations Confer Resistance, Signal Transduction +10

The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML

Anne Charlet, Max Kappenstein, Philip Keye et al. · Leukemia · 2021 · 19 citations · Full text

Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells

Anna Lena Illert, Anna Katharina Seitz, Christoph Rummelt et al. · PLoS ONE · 2014 · 10 citations · Full text

Hematological Malignancy, Biologic Activity, Aurora Kinase Inhibition +14

Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure

Jan Stratmann, Elisabeth van Kann, Christoph Rummelt et al. · Leukemia Research · 2019 · 10 citations

Hematological Malignancy, Elderly Patients, Hypomethylating-agent Failure +8